Review: Staphylococcus aureus and MRSA in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 10, Issue 5, 2011, Pages 298-306

  Goss, Christopher H ^a,b   Muhlebach, Marianne S ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cystic fibrosis; Epidemiology; Methicillin resistant Staphylococcus aureus; Staphylococcus aureus; Treatment

Indexed keywords

ANTIBIOTIC AGENT; CEFALEXIN; CHLORHEXIDINE; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; TRICYCLIC ANTIDEPRESSANT AGENT; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG PENETRATION; ERADICATION THERAPY; HUMAN; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 80052458914     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.06.002     Document Type: Review

References (82)

1. Stoltz D.A., Meyerholz D.K., Pezzulo A.A., Ramachandran S., Rogan M.P., Davis G.J., et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010, 2(29):29ra31.
2. Razvi S., Quittell L., Sewall A., Quinton H., Marshall B., Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009, 136(6):1554-1560.
3. Li Z., Kosorok M.R., Farrell P.M., Laxova A., West S.E., Green C.G., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005, 293(5):581-588.
4. Wertheim H.F., Vos M.C., Ott A., van Belkum A., Voss A., Kluytmans J.A., et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004, 364(9435):703-705.
5. Li S., Skov R.L., Han X., Larsen A.R., Larsen J., Sorum M., et al. Novel types of staphylococcal cassette chromosome mec elements identified in CC398 methicillin resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2011 Jun, 55(6):3046-3050.
6. Seybold U., Kourbatova E.V., Johnson J.G., Halvosa S.J., Wang Y.F., King M.D., et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006, 42(5):647-656.
7. Lindsay J.A. Genomic variation and evolution of Staphylococcus aureus. Int J Med Microbiol 2010, 300(2-3):98-103.
8. David M.Z., Glikman D., Crawford S.E., Peng J., King K.J., Hostetler M.A., et al. What is community-associated methicillin-resistant Staphylococcus aureus?. J Infect Dis 2008, 197(9):1235-1243.
9. Deurenberg R.H., Stobberingh E.E. The molecular evolution of hospital- and community-associated methicillin-resistant Staphylococcus aureus. Curr Mol Med 2009, 9(2):100-115.
10. Labandeira-Rey M., Couzon F., Boisset S., Brown E.L., Bes M., Benito Y., et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007, 315(5815):1130-1133.
11. Voyich J.M., Otto M., Mathema B., Braughton K.R., Whitney A.R., Welty D., et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?. J Infect Dis 2006, 194(12):1761-1770.
12. Gilpin D., McGrath S., Moffitt K., Steinhuber A., Dolhoff A., Botzenhart K., et al. MRSA from cystic fibrosis patients: a comparison of virulence factor expression under aerobic & anaerobic conditions. Pediatr Pulmonol 2010, S33:339.
13. Worlitzsch D., Kaygin H., Steinhuber A., Dalhoff A., Botzenhart K., Doring G. Effects of amoxicillin, gentamicin, and moxifloxacin on the hemolytic activity of Staphylococcus aureus in vitro and in vivo. Antimicrob Agents Chemother 2001, 45(1):196-202.
14. Smith K., Gould K.A., Ramage G., Gemmell C.G., Hinds J., Lang S. Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010, 54(1):380-387.
15. Hoffman L.R., Deziel E., D'Argenio D.A., Lepine F., Emerson J., McNamara S., et al. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 2006, 103(52):19890-19895.
16. Besier S., Smaczny C., von Mallinckrodt C., Krahl A., Ackermann H., Brade V., et al. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Microbiol 2007, 45(1):168-172.
17. Molina A., Del Campo R., Maiz L., Morosini M.I., Lamas A., Baquero F., et al. High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation. J Antimicrob Chemother 2008, 62(5):961-967.
18. Goerke C., Papenberg S., Dasbach S., Dietz K., Ziebach R., Kahl B.C., et al. Increased frequency of genomic alterations in Staphylococcus aureus during chronic infection is in part due to phage mobilization. J Infect Dis 2004, 189(4):724-734.
19. Branger C., Fournier J.M., Loulergue J., Bouvet A., Goullet P., Boutonnier A., et al. Epidemiology of Staphylococcus aureus in patients with cystic fibrosis. Epidemiol Infect 1994, 112(3):489-500.
20. Branger C., Gardye C., Lambert-Zechovsky N. Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time. J Med Microbiol 1996, 45(4):294-301.
21. Kahl B.C., Duebbers A., Lubritz G., Haeberle J., Koch H.G., Ritzerfeld B., et al. Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study. J Clin Microbiol 2003, 41(9):4424-4427.
22. Glikman D., Siegel J.D., David M.Z., Okoro N.M., Boyle-Vavra S., Dowell M.L., et al. Complex molecular epidemiology of methicillin-resistant staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S aureus. Chest 2008, 133(6):1381-1387.
23. Goodrich J.S., Sutton-Shields T.N., Kerr A., Wedd J.P., Miller M.B., Gilligan P.H. Prevalence of community-associated methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. J Clin Microbiol 2009, 47(4):1231-1233.
24. Stone A., Quittell L., Zhou J., Alba L., Bhat M., DeCelie-Germana J., et al. Staphylococcus aureus nasal colonization among pediatric cystic fibrosis patients and their household contacts. Pediatr Infect Dis J 2009, 28(10):895-899.
25. Cocchi P., Favari F., Manso E., Fiscarelli E., Busetti M., Pensabene T., et al. Diffusion of MRSA strains in the Italian CF population: a multicenter study. Pediatr Pulmonol 2010, S45:346.
26. Muhlebach M.S., Popowitch E., Miller M.B., Peng A., Lavange L., Saiman L. MRSA: Epidemiology, molecular typing and antimicrobial susceptibilities: multicenter STAR-CF study. Pediatr Pulmonol 2010, 45(S33):353.
27. Cystic Fibrosis Foundation, Patient Registry 2008 Annual Data Reprot 2009, Cystic Fibrosis Foundation, Bethesda, MD.
28. Nixon G.M., Armstrong D.S., Carzino R., Carlin J.B., Olinsky A., Robertson C.F., et al. Early airway infection, inflammation, and lung function in cystic fibrosis. Arch Dis Child 2002, 87(4):306-311.
29. Burns J.L., Emerson J., Stapp J.R., Yim D.L., Krzewinski J., Louden L., et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998, 27(1):158-163.
30. Hudson V.L., Wielinski C.L., Regelmann W.E. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J Pediatr 1993, 122(6):854-860.
31. Ranganathan S.C., Parsons F., Gangell C., Brennan S., Stick S.M., Sly P.D. Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis. Thorax 2011 May, 66(5):408-413.
32. Albus A., Fournier J.M., Wolz C., Boutonnier A., Ranke M., Hoiby N., et al. Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis. J Clin Microbiol 1988, 26(12):2505-2509.
33. Lyczak J.B., Cannon C.L., Pier G.B. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002, 15(2):194-222.
34. Rosenthal V.D., Maki D.G., Mehta A., Alvarez-Moreno C., Leblebicioglu H., Higuera F., et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008, 36(9):627-637.
35. Ren C.L., Morgan W.J., Konstan M.W., Schechter M.S., Wagener J.S., Fisher K.A., et al. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol 2007, 42(6):513-518.
36. Sawicki G.S., Rasouliyan L., Ren C.L. The impact of MRSA on lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2009, 179(8):734-735.
37. Muhlebach M.S., Miller M., Lavange L.M., Mayhew G., Goodrich J.S., Miller M.B. Treatment intensity and characteristics of MRSA infection in CF. J Cyst Fibros 2011 May, 10(3):201-206.
38. Dasenbrook E.C., Merlo C.A., Diener-West M., Lechtzin N., Boyle M.P. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008, 178(8):814-821.
39. Sanders D.B., Bittner R.C., Rosenfeld M., Hoffman L.R., Redding G.J., Goss C.H. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010, 182(5):627-632.
40. Dasenbrook E.C., Checkley W., Merlo C.A., Konstan M.W., Lechtzin N., Boyle M.P. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010, 303(23):2386-2392.
41. Elizur A., Orscheln R.C., Ferkol T.W., Atkinson J.J., Dunne W.M., Buller R.S., et al. Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest 2007, 131(6):1718-1725.
42. Tarzi S., Kennedy P., Stone S., Evans M. Methicillin-resistant Staphylococcus aureus: psychological impact of hospitalization and isolation in an older adult population. J Hosp Infect 2001, 49(4):250-254.
43. Saint S., Higgins L.A., Nallamothu B.K., Chenoweth C. Do physicians examine patients in contact isolation less frequently? A brief report. Am J Infect Control 2003, 31(6):354-356.
44. Saiman L., O'Keefe M., Graham P.L., Wu F., Said-Salim B., Kreiswirth B., et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 2003, 37(10):1313-1319.
45. Patrozou E., Reid K., Jefferson J., Mermel L.A. A cluster of community-acquired methicillin-resistant Staphylococcus aureus infections in hospital security guards. Infect Control Hosp Epidemiol 2009, 30(4):386-388.
46. D'Agata E.M., Webb G.F., Horn M.A., Moellering R.C., Ruan S. Modeling the invasion of community-acquired methicillin-resistant Staphylococcus aureus into hospitals. Clin Infect Dis 2009, 48(3):274-284.
47. Hoiby N. Hemophilus influenzae, Staphylococcus aureus, Pseudomonas cepacia, and Pseudomonas aeruginosa in patients with cystic fibrosis. Chest 1988, 94(2 Suppl):97S-103S.
48. Fitzsimmons S.C. The changing epidemiology of cystic fibrosis. J Pediatr 1993, 122(1):1-9.
49. Loening-Baucke V.A., Mischler E., Myers M.G. A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. J Pediatr 1979, 95(4):630-637.
50. Weaver L.T., Green M.R., Nicholson K., Mills J., Heeley M.E., Kuzemko J.A., et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 1994, 70(2):84-89.
51. Nolan G., Moivor P., Levison H., Fleming P.C., Corey M., Gold R. Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr 1982, 101(4):626-630.
52. Ratjen F., Comes G., Paul K., Posselt H.G., Wagner T.O., Harms K. Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol 2001, 31(1):13-16.
53. Stutman H.R., Lieberman J.M., Nussbaum E., Marks M.I. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002, 140(3):299-305.
54. Smyth A.R., Walters S. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003, 3(CD001912). 2010.
55. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel P.J., Willey-Courand D.B., et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007, 176(10):957-969.
56. Szaff M., Hoiby N. Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis. Acta Paediatr Scand 1982, 71(5):821-826.
57. Jensen T., Lanng S., Faber M., Rosdahl V.T., Hoiby N., Koch C. Clinical experiences with fusidic acid in cystic fibrosis patients. J Antimicrob Chemother 1990, 25(Suppl B):45-52.
58. Doring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004, 3(2):67-91.
59. Ridder-Schaphorn S., Ratjen F., Dubbers A., Haberle J., Falk S., Kuster P., et al. Nasal Staphylococcus aureus carriage is not a risk factor for lower-airway infection in young cystic fibrosis patients. J Clin Microbiol 2007, 45(9):2979-2984.
60. Falagas M.E., Bliziotis I.A., Fragoulis K.N. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Control 2007, 35(2):106-114.
61. Doebbeling B.N., Breneman D.L., Neu H.C., Aly R., Yangco B.G., Holley H.P., et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis 1993, 17(3):466-474.
62. Loveday H.P., Pellowe C.M., Jones S.R., Pratt R.J. A systematic review of the evidence for interventions for the prevention and control of meticillin-resistant Staphylococcus aureus (1996-2004): report to the joint MRSA working party (Subgroup A). J Hosp Infect 2006, 63(Suppl 1):S45-S70.
63. Gorwitz R.J., Jernigan D.B., Powers J.H., Jernigan J.A. Participants in the Centers for Disease Control and Prevention Convened Experts' Meeting on Management of MRSA in the Community. Strategies for Clinical Management of MRSA in the Community: Summary of an Experts' Meeting Convened by the Centers for Disease Control and Prevention 2006, 1-24. Department of Health and Human Services, Center for Disease Control and Prevention, Bethesda, MD.
64. Simor A.E., Loeb M. The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: a CIDS/CAMM position paper. Can J Infect Dis 2004, 15(1):39-48.
65. Macfarlane M., Leavy A., McCaughan J., Fair R., Reid A.J. Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J Hosp Infect 2007, 65(3):231-236.
66. Solis A., Brown D., Hughes J., Van Saene H.K., Heaf D.P. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr Pulmonol 2003, 36(3):189-195.
67. Garske L.A., Kidd T.J., Gan R., Bunting J.P., Franks C.A., Coulter C., et al. Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect 2004, 56(3):208-214.
68. Halton K., Zobell J., MacKay M., Ensign R., Chatfield B.A. Evaluation of the effectiveness of a MRSA eradication protocol in pediatric CF patients. Pediatr Pulmonol 2009, S32:339.
69. Loeb M.B., Main C., Eady A., Walkers-Dilks C. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 2003, 4(CD003340). 2003.
70. Santos R.P., Prestidge C.B., Brown M.E., Urbancyzk B., Murphey D.K., Salvatore C.M., et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pediatr Pulmonol 2009, 44(2):148-154.
71. Hill R.L., Kearns A.M., Nash J., North S.E., Pike R., Newson T., et al. Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J Antimicrob Chemother 2010, 65(3):442-445.
72. Gilbert D.N., Kohlhepp S.J., Slama K.A., Grunkemeier G., Lewis G., Dworkin R.J., et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob Agents Chemother 2001, 45(3):883-892.
73. Dalhoff A., Schubert S. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones. Int J Antimicrob Agents 2010, 36(3):216-221.
74. Madaras-Kelly K.J., Remington R.E., Lewis P.G., Stevens D.L. Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol 2006, 27(2):155-169.
75. Howden B.P., Davies J.K., Johnson P.D., Stinear T.P., Grayson M.L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010, 23(1):99-139.
76. Welte T., Pletz M.W. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents 2010, 36(5):391-400.
77. Cai Y., Wang R., Liang B., Bai N., Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011, 55(3):1162-1172.
78. Parkins M.D., Elborn J.S. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J Antimicrob Chemother 2010, 65(9):1853-1861.
79. Levy J., Smith A.L., Kenny M.A., Ramsey B., Schoenknecht F.D. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis 1983, 148(6):1069-1076.
80. Cafiso V., Bertuccio T., Spina D., Purrello S., Stefani S. Tigecycline inhibition of a mature biofilm in clinical isolates of Staphylococcus aureus: comparison with other drugs. FEMS Immunol Med Microbiol 2010, 59(3):466-469.
81. Turnidge J., Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999, 12(Suppl 2):S35-S44.
82. Murdoch M.B., Peterson L.R. Antimicrobial penetration into polymorphonuclear leukocytes and alveolar macrophages. Semin Respir Infect 1991, 6(2):112-121.